Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma

Tayao, M; Andrici, J; Farzin, M; Clarkson, A; Sioson, L; Watson, N; Chua, TC; Sztynda, T; Samra, JS; Gill, AJ

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma

Tayao, M Andrici, J Farzin, M Clarkson, A Sioson, L Watson, N Chua, TC Sztynda, T

Samra, JS Gill, AJ

Permalink

Publication Type:: Journal Article
Citation:: PloS one, 2016, 11 (3), pp. e0150338 - ?
Issue Date:: 2016-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Submitted VersionAdobe PDF (1.97 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Tayao, M	en_US
dc.contributor.author	Andrici, J	en_US
dc.contributor.author	Farzin, M	en_US
dc.contributor.author	Clarkson, A	en_US
dc.contributor.author	Sioson, L	en_US
dc.contributor.author	Watson, N	en_US
dc.contributor.author	Chua, TC	en_US
dc.contributor.author	Sztynda, T https://orcid.org/0000-0002-8957-0864	en_US
dc.contributor.author	Samra, JS	en_US
dc.contributor.author	Gill, AJ	en_US
dc.date.available	2016-02-12	en_US
dc.date.issued	2016-01-01	en_US
dc.identifier.citation	PloS one, 2016, 11 (3), pp. e0150338 - ?	en_US
dc.identifier.uri	http://hdl.handle.net/10453/119135
dc.description.abstract	BACKGROUND: Pancreatic cancer is both common and highly lethal and therefore new biomarkers or potential targets for treatment are needed. Loss of BRCA associated protein-1 (BAP1) expression has been found in up to a quarter of intrahepatic cholangiocarcinomas. Given the close anatomical relationship between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma, we therefore sought to investigate the frequency of loss of BAP1 expression in pancreatic ductal adenocarcinoma. METHODS: The records of the department of Anatomical Pathology Royal North Shore Hospital, Sydney, Australia, were searched for cases of pancreatic ductal adenocarcinoma diagnosed between 1992 and 2014 with material available in archived formalin fixed paraffin embedded tissue blocks. Immunohistochemistry for BAP1 was performed on tissue microarray sections and if staining was equivocal or negative it was confirmed on whole sections. Negative staining for BAP1 was defined as loss of expression in all neoplastic nuclei, with preserved expression in non-neoplastic cells which acted as an internal positive control. RESULTS: Loss of BAP1 expression was found in only 1 of 306 (0.33%) pancreatic ductal adenocarcinomas. This case was confirmed to demonstrate diffuse loss of expression throughout all neoplastic cells in multiple blocks, consistent with BAP1 loss being an early clonal event. All other cases demonstrated positive expression of BAP1. CONCLUSION: We conclude that, in contrast to intrahepatic cholangiocarcinoma, loss of expression of BAP1 occurs very rarely in pancreatic ductal adenocarcinoma. Therefore BAP1 inactivation is unlikely to be a frequent driver abnormality in pancreatic adenocarcinoma.	en_US
dc.relation.ispartof	PloS one	en_US
dc.relation.isbasedon	10.1371/journal.pone.0150338	en_US
dc.subject.classification	General Science & Technology	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Adenocarcinoma	en_US
dc.subject.mesh	Carcinoma, Pancreatic Ductal	en_US
dc.subject.mesh	Pancreatic Neoplasms	en_US
dc.subject.mesh	Ubiquitin Thiolesterase	en_US
dc.subject.mesh	Tumor Suppressor Proteins	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Aged	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Male	en_US
dc.title	Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	11	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	11	en_US

Abstract:

BACKGROUND: Pancreatic cancer is both common and highly lethal and therefore new biomarkers or potential targets for treatment are needed. Loss of BRCA associated protein-1 (BAP1) expression has been found in up to a quarter of intrahepatic cholangiocarcinomas. Given the close anatomical relationship between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma, we therefore sought to investigate the frequency of loss of BAP1 expression in pancreatic ductal adenocarcinoma. METHODS: The records of the department of Anatomical Pathology Royal North Shore Hospital, Sydney, Australia, were searched for cases of pancreatic ductal adenocarcinoma diagnosed between 1992 and 2014 with material available in archived formalin fixed paraffin embedded tissue blocks. Immunohistochemistry for BAP1 was performed on tissue microarray sections and if staining was equivocal or negative it was confirmed on whole sections. Negative staining for BAP1 was defined as loss of expression in all neoplastic nuclei, with preserved expression in non-neoplastic cells which acted as an internal positive control. RESULTS: Loss of BAP1 expression was found in only 1 of 306 (0.33%) pancreatic ductal adenocarcinomas. This case was confirmed to demonstrate diffuse loss of expression throughout all neoplastic cells in multiple blocks, consistent with BAP1 loss being an early clonal event. All other cases demonstrated positive expression of BAP1. CONCLUSION: We conclude that, in contrast to intrahepatic cholangiocarcinoma, loss of expression of BAP1 occurs very rarely in pancreatic ductal adenocarcinoma. Therefore BAP1 inactivation is unlikely to be a frequent driver abnormality in pancreatic adenocarcinoma.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/119135